GEN Exclusives

More »

GEN News Highlights

More »
Jul 31, 2014

Molecular Profiles Partners with XenoGesis to Advance Formulation Development

  • Molecular Profiles, a subsidiary of Columbia Laboratories, and XenoGesis, a laboratory-based CRO, have joined together to help pharmaceutical and biotech drug developers during the preclinical and formulation-development stage.

    Molecular Profiles’ pharmaceutical development services will be supported by XenoGesis’ expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a better understanding of a compound’s bioavailability. 

    The Nottingham-based companies plan to help drug developers in the initial design and selection of compounds for key DMPK and ADME studies, as well as supporting lead candidates, which have solubility issues during formulation development.

    Molecular Profiles recently created a new enabling technologies team and invested in GMP hot melt extrusion technology at its clinical manufacturing facility to enhance its expertise in the processing of difficult-to-progress molecules. Alongside its development capabilities, its MHRA-licensed site enables the company to manufacture a range of dosage forms for clinical trials spanning solids, liquids, semi-solids, and inhaled products, including potent compounds and controlled drugs.

    ”We have complementary service offerings which allow us to apply a science-driven, collective approach to overcome the complexities of challenging molecules. It also adds a vital pK service to our enabling technologies package,” said Frank Condella, president and CEO at Columbia Laboratories. “This will build-upon the very successful drug development alliances we already have in place. We can now seamlessly offer a comprehensive service from initial drug discovery through to clinical supplies with best-in-class companies.”

    “Combining our skills in DMPK with the chemical knowledge at Molecular Profiles will provide a solid platform to support clients,” said Richard Weaver Ph.D., managing director of Xenogesis. “We will be able to give them a better understanding of their compounds during preclinical work, which in turn, will reduce cost and provide a quicker route to market.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?